Regenxbio
RGNX
86 hedge funds and large institutions have $448M invested in Regenxbio in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 46 increasing their positions, 19 reducing their positions, and 12 closing their positions.
142% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 19
89% more call options, than puts
Call options by funds: $17K | Put options by funds: $9K
12% more capital invested
Capital invested by funds: $401M → $448M (+$46.4M)
4.9% more ownership
Funds ownership: 68.61% → 73.51% (+4.9%)
1% more funds holding
Funds holding: 85 → 86 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$10.8M |
| 3 |
BlackRock
New York
|
+$8.95M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$8.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10.2M |
| 2 |
Millennium Management
New York
|
-$8.17M |
| 3 |
Axa
Paris,
France
|
-$4.37M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$3.97M |
| 5 |
QF
QVT Financial
New York
|
-$3.73M |
RGNX Hedge Fund Activity: Q2 2017 in Review
86 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2017, worth a combined $448M — up 12% from $401M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RGNX positions and 12 closed out — a net gain of 1 holder — while 46 added to existing stakes and 19 trimmed.
The largest buyer was State Street, adding an estimated $10.9M. The largest seller was PFM Health Sciences, cutting an estimated $10.2M.
- 86 institutional investors held Regenxbio (RGNX) as of Q2 2017, up from 85 in Q1 2017.
- Funds reported $448M of Regenxbio stock for Q2 2017, up 12% quarter-over-quarter.
- 13 funds opened new Regenxbio positions in Q2 2017 and 12 closed out, a net change of +1 holder.
- The largest Regenxbio buyer in Q2 2017 was State Street, an estimated $10.9M added.
- The largest Regenxbio seller in Q2 2017 was PFM Health Sciences, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2017.